Document:

<PAGE>
                                                                   EXHIBIT 10.15

                               WARRANT TO PURCHASE
                     COMMON STOCK, PAR VALUE $.01 PER SHARE

                                       OF

                              HALSEY DRUG CO., INC.

THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") NOR UNDER
ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR
OTHERWISE TRANSFERRED UNTIL (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS
EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE
COMPANY RECEIVES AN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL TO THE
HOLDER OF SUCH WARRANT REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH WARRANT
AND/OR COMMON STOCK MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR TRANSFERRED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS.

                  This certifies that, for value received, WATSON
PHARMACEUTICALS, INC., or its registered assigns ("Warrantholder"), is entitled
to purchase from HALSEY DRUG CO., INC. (the "Company"), subject to the
provisions of this Warrant, at any time during the Exercise Period (as
hereinafter defined) 10,700,665 shares of the Company's Common Stock, par value
$.01 per share ("Warrant Shares"). The purchase price payable upon the exercise
of this Warrant shall be $.34 per Warrant Share. The purchase price and the
number of Warrant Shares which the Warrantholder is entitled to purchase are
subject to adjustment upon the occurrence of the contingencies set forth in this
Warrant, and as adjusted from time to time, such purchase price is hereinafter
referred to as the "Warrant Price".

                  For purposes of this Warrant, the term "Exercise Period" means
the period commencing on the date of issuance of this Warrant and ending on
December 31, 2009.

                  This Warrant is subject to the following terms and conditions:

                  1.       Exercise of Warrant.

                           (a)       This Warrant may be exercised in whole
or in part but not for a fractional share. Upon delivery of this Warrant at the
offices of the Company or at such other address as the Company may designate by
notice in writing to the registered holder hereof with the Subscription Form
annexed hereto duly executed, accompanied by payment of the Warrant Price for
the number of Warrant Shares purchased (in cash, by certified, cashier's or
other check acceptable to the Company), the registered holder of this Warrant
shall be entitled to receive a certificate or certificates for the Warrant
Shares so purchased. Such certificate or certificates shall be promptly

                                        1
<PAGE>
delivered to the Warrantholder. Upon any partial exercise of this Warrant, the
Company shall execute and deliver a new Warrant of like tenor for the balance of
the Warrant Shares purchasable hereunder.

                           (b)      In lieu of exercising this Warrant
pursuant to Section 1(a), the holder may elect to receive shares of Common Stock
equal to the value of this Warrant determined in the manner described below (or
any portion thereof remaining unexercised) upon delivery of this Warrant at the
offices of the Company or at such other address as the Company may designate by
notice in writing to the registered holder hereof with the Notice of Cashless
Exercise Form annexed hereto duly executed. In such event the Company shall
issue to the holder a number of shares of the Company's Common Stock computed
using the following formula:

                                 X = Y (A-B)
                                     -------
                                        A

Where X = the number of shares of Common Stock to be issued to the holder.

      Y = the number of shares of Common Stock purchasable under this Warrant
            (at the date of such calculation).

      A = the Market Value of the Company's Common Stock on the business day
          immediately preceding the day on which the Notice of Cashless Exercise
          is received by the Company.

      B = Warrant Price (as adjusted to the date of such calculation).

                           (c)      The Warrant Shares deliverable hereunder
shall, upon issuance, be fully paid and non-assessable and the Company agrees
that at all times during the term of this Warrant it shall cause to be reserved
for issuance such number of shares of its Common Stock as shall be required for
issuance and delivery upon exercise of this Warrant.

                           (d)      For purposes of Section 1(b) of this
Warrant, the Market Value of a share of Common Stock on any date shall be equal
to (i) the closing sale price per share as published by a national securities
exchange on which shares of Common Stock are traded (an "Exchange") on such date
or, if there is no sale of Common Stock on such date, the average of the bid and
asked prices on such Exchange at the close of trading on such date or, (ii) if
shares of Common Stock are not listed on an Exchange on such date, the closing
price per share as published on the National Association of Securities Dealers
Automatic Quotation System ("NASDAQ") National Market System if the shares are
quoted on such system on such date, or (iii) the average of the bid and asked
prices in the over-the-counter market at the close of trading on such date if
the shares are not traded on an Exchange or listed on the NASDAQ National Market
System, or (iv) if the security is not traded on an Exchange or in the
over-the-counter market, the fair market value of a share of Common Stock on
such date as determined in good faith by the Board of Directors of the Company.
If the holder disagrees with the determination of the Market Value of any
securities of the Common Stock determined by the Board of Directors under
Section 1(d)(iv) the Market Value shall be

                                        2
<PAGE>
determined by an independent appraiser acceptable to the Company and the holder.
If they cannot agree on such an appraiser, then each of the Company and the
holder shall select an independent appraiser, such two appraisers shall select a
third independent appraiser and Market Value shall be the median of the
appraisals made by such appraisers. If there is one appraiser, the cost of the
appraisal shall be shared equally between the Company and the holder. If there
are three appraisers, each of the Company and the holder shall pay for its own
appraiser and shall share equally the cost of the third appraiser.

                  2.       Transfer or Assignment of Warrant.

                           (a)      Any assignment or transfer of this
Warrant shall be made by surrender of this Warrant at the offices of the Company
or at such other address as the Company may designate in writing to the
registered holder hereof with the Assignment Form annexed hereto duly executed
and accompanied by payment of any requisite transfer taxes, and the Company
shall, without charge, execute and deliver a new Warrant of like tenor in the
name of the assignee for the portion so assigned in case of only a partial
assignment, with a new Warrant of like tenor to the assignor for the balance of
the Warrant Shares purchasable.

                           (b)      Prior to any assignment or transfer of this
Warrant, the holder thereof shall deliver an opinion of counsel to the Company
to the effect that the proposed transfer may be effected without registration
under the Act. Each Warrant issued upon or in connection with such transfer
shall bear the restrictive legend set forth on the front of this Warrant unless,
in the opinion of the Company's counsel, such legend is no longer required to
insure compliance with the Act.

                  3.       Adjustments to Warrant Price and Warrant Shares --
Anti-Dilution Provisions. In order to prevent dilution of the exercise right
granted hereunder, the Warrant Price shall be subject to adjustment from time to
time in accordance with this Section 3.

                  The Warrant Price in effect at the time of the exercise of
this Warrant shall be subject to adjustment from time to time as follows:

                  (a)      In the event that the Company shall at any time: (i)
declare or pay to the holders of the Common Stock a dividend payable in any kind
of shares of capital stock of the Company; or (ii) change or divide or otherwise
reclassify its Common Stock into the same or a different number of shares with
or without par value, or in shares of any class or classes; or (iii) transfer
its property as an entirety or substantially as an entirety to any other company
or entity; or (iv) make any distribution of its assets to holders of its Common
Stock as a liquidation or partial liquidation dividend or by way of return of
capital; then, upon the subsequent exercise of this Warrant, the holder thereof
shall receive, in addition to or in substitution for the shares of Common Stock
to which it would otherwise be entitled upon such exercise, such additional
shares of stock or scrip of the Company, or such reclassified shares of stock of
the Company, or such shares of the securities or property of the company
resulting from transfer, or such assets of the Company, which it would have been
entitled to receive had it exercised these rights prior to the happening of any
of the foregoing events. If, at any time during the Exercise Period, the number
of outstanding shares of Common Stock is (i) increased by a stock dividend
payable in shares of Common Stock or by a

                                        3
<PAGE>
subdivision or split up of shares of Common Stock, or (ii) decreased by a
combination of shares of Common Stock, then, simultaneously with the occurrence
of such event, the Warrant Price shall be adjusted automatically to a new amount
equal to the product of (A) the Warrant Price in effect on such record date and
(B) the quotient obtained by dividing (x) the number of shares of Common Stock
outstanding on such record date (without giving effect to the events referred to
in the foregoing clauses (i) or (ii)) by (y) the number of shares of Common
Stock which would be outstanding immediately after the event referred to in the
foregoing clauses (i) or (ii).

                  (b)      Until such time as the Company completes a Subsequent
Material Offering (as defined in Section 3(k) hereof), if the Company shall
grant or issue any shares of Common Stock, or grant or issue any rights or
options for the purchase of, or stock or other securities convertible into,
Common Stock (such convertible stock or securities being herein collectively
referred to as "Convertible Securities"), including in connection with a
Subsequent Material Offering, other than:

                  (i)      shares issued in a transaction described in
                           subsection (d) of this Section 3; or

                  (ii)     shares issued, subdivided or combined in transactions
                           described in Section 3(a) if and to the extent that
                           the number of shares of Common Stock received upon
                           exercise of this Warrant shall have been previously
                           adjusted pursuant to Section 3(a) as a result of such
                           issuance, subdivision or combination of such
                           securities;

for a consideration per share which is less than the Warrant Price in effect
immediately prior to such issuance or sale (the "Applicable Warrant Price"),
then the Applicable Warrant Price in effect immediately prior to such issuance
or sale shall, and thereafter, except as otherwise provided in Subsection 3(c)
hereof, upon each issuance or sale for a consideration per share which is less
than the Applicable Warrant Price, the Applicable Warrant Price shall,
simultaneously with such issuance or sale, be adjusted, so that such Applicable
Warrant Price shall equal (A) the price per share received by the Company, in
the case of the issuance of Common Stock by the Company, or (B) the exercise or
conversion price of the Convertible Securities issued by the Company, as
applicable.

                  (c)      If at any time following the Company's completion of
a Subsequent Material Offering the Company shall grant or issue any shares of
Common Stock, or grant or issue any Convertible Securities, other than:

                  (i)      shares issued in a transaction described in
                           subsection (d) of this Section 3; or

                  (ii)     shares issued, subdivided or combined in transactions
                           described in Section 3(a) if and to the extent that
                           the number of shares of Common Stock received upon
                           conversion of this Debenture shall have been
                           previously adjusted pursuant to

                                        4
<PAGE>
                           Section 3(a) as a result of such issuance,
                           subdivision or combination of such securities;

for a consideration per share which is less than the Fair Market Value (as
hereinafter defined) of the Common Stock, then the Applicable Warrant Price
shall, and thereafter upon each issuance or sale for a consideration per share
which is less than the Fair Market Value of the Common Stock, the Applicable
Warrant Price shall, simultaneously with such issuance or sale, be adjusted, so
that the Applicable Warrant Price shall equal a price determined by multiplying
the Applicable Warrant Price by a fraction, of which:

                  (A)      the numerator of which shall be the sum of (x) the
                  total number of shares of Common Stock outstanding when the
                  Applicable Warrant Price became effective, plus (y) the number
                  of shares of Common Stock which the aggregate consideration
                  received, as determined in accordance with Section 3(e) for
                  the issuance or sale of such additional Common Stock or
                  Convertible Securities deemed to be an issuance of Common
                  Stock as provided in Section 3(f), would purchase (including
                  any consideration received by the Company upon the issuance of
                  any shares of Common Stock since the date the Applicable
                  Warrant Price became effective not previously included in any
                  computation resulting in an adjustment pursuant to this
                  subsection 3(c)) at the Fair Market Value of the Common Stock;
                  and

                  (B)      the denominator of which shall be the total number of
                  shares of Common Stock outstanding (or deemed to be
                  outstanding as provided in subsection 3(f) hereof) immediately
                  after the issuance or sale of such additional shares.

                  For purposes of this Section 3, "Fair Market Value" shall mean
the average of the closing price of the Common Stock for each of the twenty (20)
consecutive trading days prior to such issuance or sale on an Exchange or if
shares of Common Stock are not listed on an Exchange during such period, the
closing price per share as reported by NASDAQ National Market System if the
shares are quoted on such system during such period, or the average of the bid
and asked prices of the Common Stock in the over-the-counter market at the close
of trading during such period if the shares are not traded on an Exchange or
listed on the NASDAQ National Market System, or if the Common Stock is not
traded on an Exchange or in the over-the-counter market, the fair market value
of a share of Common Stock during such period as determined in good faith by the
Board of Directors.

                  If, however, the Applicable Warrant Price thus obtained would
result in the issuance of a lesser number of shares upon conversion than would
be issued at the initial Warrant Price, the Applicable Warrant Price shall be
such initial Warrant Price.

                  Upon each adjustment of the Warrant Price solely pursuant to
this subsection 3(c), the Warrantholder shall thereafter be entitled to acquire
upon exercise under Section 1, at the Applicable Warrant Price, the number of
shares of Common Stock obtainable by multiplying the Warrant Price in effect
immediately prior to such adjustment by the number of shares of Common

                                        5
<PAGE>
Stock acquirable immediately prior to such adjustment and dividing the product
thereof by the Applicable Warrant Price resulting from such adjustment.

                  (d)      Anything in this Section 3 to the contrary
notwithstanding, no adjustment in the Warrant Price shall be made in connection
with:

                  (i)      the grant, issuance or exercise of any Convertible
                           Securities pursuant to the Company's qualified or
                           non-qualified Employee Stock Option Plans or any
                           other bona fide employee benefit plan or incentive
                           arrangement, adopted or approved by the Company's
                           Board of Directors or approved by the Company's
                           shareholders, as may be amended from time to time, or
                           under any other bona fide employee benefit plan
                           hereafter adopted by the Company's Board of
                           Directors; or

                  (ii)     the grant, issuance or exercise of any Convertible
                           Securities in connection with the hire or retention
                           of any officer, director or key employee of the
                           Company, provided such grant is approved by the
                           Company's Board of Directors; or

                  (iii)    the issuance of any shares of Common Stock or
                           Convertible Securities issued in satisfaction of
                           interest payments on all of the Company's 5%
                           convertible senior secured debentures due March 31,
                           2006, including (i) the 5% convertible senior
                           secured debentures issued pursuant to the Debenture
                           and Warrant Purchase Agreement dated as of March 10,
                           1998 between the Company, Galen Partners III, L.P.
                           and the other signatories thereto, the Debenture and
                           Warrant Purchase Agreement dated as of May 26, 1999
                           between the Company, Oracle Strategic Partners, L.P.
                           and the other signatories thereto, and the Debenture
                           Purchase Agreement dated December 20, 2002 between
                           the Company, Care Capital LLC, Essex Woodlands
                           Health Ventures Fund V and the other signatories
                           thereto, and (ii) the issuance of Common Stock or
                           Convertible Securities issued in satisfaction of
                           interest payments on debentures instruments issued
                           by the Company in satisfaction of interest payments
                           on the Company's 5% convertible senior secured
                           debentures due March 31, 2006; or

                  (iv)     the issuance of any shares of Common Stock pursuant
                           to the grant or exercise or conversion of Convertible
                           Securities outstanding as of the date hereof
                           (exclusive of any subsequent amendments thereto); or

                  (v)      the issuance of the Company's 5% convertible senior
                           secured debentures due March 31, 2006 issued pursuant
                           to that certain Debenture Purchase Agreement dated
                           December 20, 2002 between the Company, Care Capital,
                           LLC, Essex Woodlands Health Ventures Fund V and the
                           other purchasers listed on the signature page
                           thereto; or

                                        6
<PAGE>
                  (vi)     the issuance of 5,970,083 shares of the Company's
                           Common Stock pursuant to that certain Warrant
                           Recapitalization Agreement dated December 20, 2002
                           between the Company, Oracle Strategic Partners, L.P.
                           and the other parties listed on the signature page
                           thereto.

                  (e)      For the purpose of Sections 3(b), 3(c) and 3(d), the
following provisions shall also be applied:

                  (i)      In case of the issuance or sale of additional shares
                           of Common Stock for cash, the consideration received
                           by the Company therefor shall be deemed to be the
                           amount of cash received by the Company for such
                           shares, before deducting therefrom any commissions,
                           compensation or other expenses paid or incurred by
                           the Company for any underwriting of, or otherwise in
                           connection with, the issuance or sale of such shares.

                  (ii)     In the case of the issuance of Convertible
                           Securities, the consideration received by the Company
                           therefor shall be deemed to be the amount of cash, if
                           any, received by the Company for the issuance of such
                           rights or options, plus the minimum amounts of cash
                           and fair market value of other consideration, if any,
                           payable to the Company upon the exercise of such
                           rights or options or payable to the Company upon
                           conversion of such Convertible Securities.

                  (iii)    In the case of the issuance of shares of Common Stock
                           or Convertible Securities for a consideration in
                           whole or in part, other than cash, the consideration
                           other than cash shall be deemed to be the fair
                           market value thereof as reasonably determined in
                           good faith by the Board of Directors of the Company
                           (irrespective of accounting treatment thereof);
                           provided, however, that if such consideration
                           consists of the cancellation of debt issued by the
                           Company, the consideration shall be deemed to be the
                           amount the Company received upon issuance of such
                           debt (gross proceeds) plus accrued interest and, in
                           the case of original issue discount or zero coupon
                           indebtedness, accrued value to the date of such
                           cancellation, but not including any premium or
                           discount at which the debt may then be trading or
                           which might otherwise be appropriate for such class
                           of debt.

                  (iv)     In case of the issuance of additional shares of
                           Common Stock upon the conversion or exchange of any
                           obligations (other than Convertible Securities), the
                           amount of the consideration received by the Company
                           for such Common Stock shall be deemed to be the
                           consideration received by the Company for such
                           obligations or shares so converted or exchanged,
                           before deducting from such consideration so received
                           by the Company any expenses or commissions or
                           compensation incurred or paid by the Company for any
                           underwriting of, or otherwise in connection with,
                           the issuance or sale of such

                                        7
<PAGE>
                           obligations or shares, plus any consideration
                           received by the Company in connection with such
                           conversion or exchange other than a payment in
                           adjustment of interest and dividends. If
                           obligations or shares of the same class or series of
                           a class as the obligations or shares so converted or
                           exchanged have been originally issued for different
                           amounts of consideration, then the amount of
                           consideration received by the Company upon the
                           original issuance of each of the obligations or
                           shares so converted or exchanged shall be deemed to
                           be the average amount of the consideration received
                           by the Company upon the original issuance of all
                           such obligations or shares. The amount of
                           consideration received by the Company upon the
                           original issuance of the obligations or shares so
                           converted or exchanged and the amount of the
                           consideration, if any, other than such obligations
                           or shares, received by the Company upon such
                           conversion or exchange shall be determined in the
                           same manner as provided in paragraphs (i) and (ii)
                           above with respect to the consideration received by
                           the Company in case of the issuance of additional
                           shares of Common Stock or Convertible Securities.

                  (v)      In the case of the issuance of additional shares of
                           Common Stock as a dividend, the aggregate number of
                           shares of Common Stock issued in payment of such
                           dividend shall be deemed to have been issued at the
                           close of business on the record date fixed for the
                           determination of stockholders entitled to such
                           dividend and shall be deemed to have been issued
                           without consideration; provided, however, that if the
                           Company, after fixing such record date, shall legally
                           abandon its plan to so issue Common Stock as a
                           dividend, no adjustment of the Applicable Conversion
                           Price shall be required by reason of the fixing of
                           such record date.

                  (f)      For purposes of the adjustment provided for in
Sections 3(b) and 3(c) above, if at any time the Company shall issue any
Convertible Securities, the Company shall be deemed to have issued at the time
of the issuance of such Convertible Securities the maximum number of shares of
Common Stock issuable upon conversion of the total amount of such Convertible
Securities.

                  (g)      On the expiration, cancellation or redemption of any
Convertible Securities, the Warrant Price then in effect hereunder shall
forthwith be readjusted to such Warrant Price as would have been obtained (i)
had the adjustments made upon the issuance or sale of such expired, canceled or
redeemed Convertible Securities been made upon the basis of the issuance of only
the number of shares of Common Stock theretofore actually delivered upon the
exercise or conversion of such Convertible Securities (and the total
consideration received therefor) and (ii) had all subsequent adjustments been
made on only the basis of the Warrant Price as readjusted under this Section
3(g) for all transactions (which would have affected such adjusted Warrant
Price) made after the issuance or sale of such Convertible Securities.

                  (h)      Anything in this Section 3 to the contrary
notwithstanding, no adjustment in the Warrant Price shall be required unless
such adjustment would require an increase or decrease of at least 1% in such
Warrant Price; provided, however, that any adjustments which by reason of this

                                        8
<PAGE>
Section 3(h) are not required to be made shall be carried forward and taken into
account in making subsequent adjustments. All calculations under this Section 3
shall be made to the nearest cent.

                  (i)      If, at any time while this Warrant is outstanding,
the Company shall pay any dividend payable in cash or in Common Stock, shall
offer to the holders of its Common Stock for subscription or purchase by them
any shares of stock of any class or any other rights, shall enter into an
agreement to merge or consolidate with another corporation, shall propose any
capital reorganization or reclassification of the capital stock of the Company,
including any subdivision or combination of its outstanding shares of Common
Stock or there shall be contemplated a voluntary or involuntary dissolution,
liquidation or winding up of the Company, the Company shall cause notice thereof
to be mailed to the registered holder of this Warrant at its address appearing
on the registration books of the Company, at least 30 days prior to the record
date as of which holders of Common Stock shall participate in such dividend,
distribution or subscription or other rights or at least 30 days prior to the
effective date of the merger, consolidation, reorganization, reclassification or
dissolution. Upon any adjustment of any Warrant Price, then and in each such
case the Company shall promptly deliver a notice to the registered holder of
this Warrant, which notice shall state the Warrant Price resulting from such
adjustment, setting forth in reasonable detail the method of calculation and the
facts upon which such calculation is based.

                  (j)      If the Company is a party to a merger or other
transaction which reclassifies or changes its outstanding Common Stock, upon
consummation of such transaction this Warrant shall automatically become
exercisable for the kind and amount of securities, cash or other assets which
the holder of this Warrant would have owned immediately after such transaction
if the holder had converted this Warrant at the Warrant Price in effect
immediately before the effective date of the transaction. Concurrently with the
consummation of such transaction, the person obligated to issue securities or
deliver cash or other assets upon exercise of this Warrant shall execute and
deliver to the holder a supplemental Warrant so providing and further providing
for adjustments which shall be as nearly equivalent as may be practical to the
adjustments provided in this Section 3. The successor company shall mail to the
holder a notice describing the supplemental Warrant.

                  If securities deliverable upon exercise of this Warrant, as
provided above, are themselves convertible into or exercisable for the
securities of an affiliate of a corporation formed, surviving or otherwise
affected by the merger or other transaction, that issuer shall join in the
supplemental Warrant which shall so provide. If this Section 3(j) applies,
Section 3(a) does not apply.

                  (k)      For purposes hereof, "Subsequent Material Offering"
shall mean the grant or issuance of shares of Common Stock, or the grant or
issuance of Convertible Securities, during any six (6) month period for an
aggregate gross consideration (determined in accordance with Section 3(e)
hereof) of at least ten million dollars ($10,000,000) for a consideration per
share that is in excess of the then Applicable Exercise Price.

                  4.       Charges, Taxes and Expenses. The issuance of
certificates for Warrant Shares upon any exercise of this Warrant shall be made
without charge to the holder of this Warrant for any tax or other expense in
respect to the issuance of such certificates, all of which taxes and

                                        9
<PAGE>
expenses shall be paid by the Company, and such certificates shall be issued
only in the name of the holder of this Warrant.

                  5.       Miscellaneous.

                           (a)      The terms of this Warrant shall be binding
upon and shall inure to the benefit of any successors or assigns of the Company
and of the holder or holders hereof and of the shares of Common Stock issued or
issuable upon the exercise hereof.

                           (b)      No holder of this Warrant, as such, shall
be entitled to vote or receive dividends or be deemed to be a stockholder of the
Company for any purpose, nor shall anything contained in this Warrant be
construed to confer upon the holder of this Warrant, as such, any rights of a
stockholder of the Company or any right to vote, give or withhold consent to any
corporate action, receive notice of meetings, receive dividends or subscription
rights, or otherwise.

                           (c)      Receipt of this Warrant by the holder
hereof shall constitute acceptance of an agreement to the foregoing terms and
conditions.

                           (d)      The Warrant and the performance of the
parties hereunder shall be construed and interpreted in accordance with the laws
of the State of New York without giving effect to its conflict of laws rules
wherein it was negotiated and executed and the parties hereunder consent and
agree that the State and Federal Courts which sit in the State of New York and
the County of New York shall have exclusive jurisdiction with respect to all
controversies and disputes arising hereunder.

                                       10
<PAGE>
                  IN WITNESS WHEREOF, the Company has caused this Warrant to be
signed by its duly authorized officer and its corporate seal to be affixed
hereto.

Dated as of December  20, 2002

                                     HALSEY DRUG CO., INC.

                                     BY:________________________________________
                                         Name:  Michael Reicher
                                         Title: Chief Executive Officer
<PAGE>
                                SUBSCRIPTION FORM

                    (TO BE EXECUTED BY THE REGISTERED HOLDER
                     IF HE DESIRES TO EXERCISE THE WARRANT)

         To:      HALSEY DRUG CO., INC.

                  The undersigned hereby exercises the right to purchase
_________ shares of Common Stock, par value $.01 per share, covered by the
attached Warrant in accordance with the terms and conditions thereof, and
herewith makes payment of the Warrant Price for such shares in full.

                                       _________________________________________
                                       SIGNATURE

                                       _________________________________________
                                       ADDRESS

                                       _________________________________________

DATED:______________
<PAGE>
                   NOTICE OF EXERCISE OF COMMON STOCK WARRANT
             PURSUANT TO NET ISSUE ("CASHLESS") EXERCISE PROVISIONS

                                                               [ Date ]

<TABLE>
<S>                                    <C>                     <C>
Halsey Drug Co., Inc.                  Aggregate Price of      $________________
a New York corporation                 of Warrant
695 N. Perryville Road                 Aggregate Price Being
Rockford, Illinois 61107               Exercised:              $________________
Attention: _______________

                                       Warrant Price (per
                                       share):                 $________________

                                       Market Value (per
                                       share):                 $________________

                                       Number of Shares of
                                       Common Stock under
                                       this Warrant:           _________________

                                       Number of Shares of
                                       Common Stock to be
                                       Issued Under this
                                       Notice:                 _________________
</TABLE>

                                CASHLESS EXERCISE

Gentlemen:

                  The undersigned, the registered holder of the Warrant to
Purchase Common Stock delivered herewith ("Warrant"), hereby irrevocably
exercises such Warrant for, and purchases thereunder, shares of the Common Stock
of HALSEY DRUG CO., INC., a New York corporation, as provided below. Capitalized
terms used herein, unless otherwise defined herein, shall have the meanings
given in the Warrant. The portion of the Aggregate Price (as hereinafter
defined) to be applied toward the purchase of Common Stock pursuant to this
Notice of Exercise is $______, thereby leaving a remainder Aggregate Price (if
any) equal to $______. Such exercise shall be pursuant to the net issue exercise
provisions of Section 1(b) of the Warrant; therefore, the holder makes no
payment with this Notice of Exercise. The number of shares to be issued pursuant
to this exercise shall be determined by reference to the formula in Section 1(b)
of the Warrant which requires the use of the Market Value (as defined in Section
1(d) of the Warrant) of the Company's Common Stock on the business day
immediately preceding the day on which this Notice is received by the Company.
To the extent the foregoing exercise is for less than the full Aggregate Price
of the Warrant, the remainder of the Warrant representing a number of Shares
equal to the quotient obtained by dividing the remainder of the Aggregate Price
by the Warrant Price (and otherwise of like form, tenor and effect) may be
exercised under Section 1(a) of the Warrant. For purposes of this
<PAGE>
Notice the term "Aggregate Price" means the product obtained by multiplying the
number of shares of Common Stock for which the Warrant is exercisable times the
Warrant Price.

                                       _________________________________________
                                       SIGNATURE

DATE:_______________                   _________________________________________
                                       ADDRESS

                                       2
<PAGE>
                                   ASSIGNMENT

                    (TO BE EXECUTED BY THE REGISTERED HOLDER
                     IF HE DESIRES TO TRANSFER THE WARRANT)

                  FOR VALUE RECEIVED, the undersigned hereby sells, assigns and
transfers unto________ the right to purchase shares of Common Stock of HALSEY
DRUG CO., INC., evidenced by the within Warrant, and does hereby irrevocably
constitute and appoint_____________ Attorney to transfer the said Warrant on the
books of the Company, with full power of substitution.

                                       _________________________________________
                                       SIGNATURE

                                       _________________________________________
                                       ADDRESS

DATED:______________

IN THE PRESENCE OF:

____________________

                                       3<PAGE>
                                                                   EXHIBIT 10.16

                          REGISTRATION RIGHTS AGREEMENT

                  THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") dated as
of December 20, 2002, by and between HALSEY DRUG CO., INC., a New York
corporation (the "Company") and the investors listed on Schedule 1 attached
hereto (each an "Investor"; collectively, the "Investors").

                  WHEREAS, the Company and certain purchasers are parties to
that certain Debenture and Warrant Purchase Agreement dated March 10, 1998 (as
such agreement may be supplemented, amended, or otherwise modified from time to
time, the "1998 Purchase Agreement"), whereby the Company issued to such parties
the Company's 5% convertible secured debentures due March 15, 2003 (as such
debentures may be supplemented, amended, or otherwise modified from time to
time, the "1998 Debentures"; each such holder of 1998 Debentures, or any
permitted successor, assign or transferee thereof, a "1998 Holder") and warrants
to purchase Common Stock (the "1998 Warrants");

                  WHEREAS, in connection with the 1998 Purchase Agreement, the
Company granted to the 1998 Holders registration rights as set forth in Article
XI of the 1998 Purchase Agreement;

                  WHEREAS, the Company and certain purchasers are parties to
that certain Debenture and Warrant Purchase Agreement dated May 26, 1999 (as
such agreement may be supplemented, amended, or otherwise modified from time to
time, the "1999 Purchase Agreement"), whereby the Company issued to such parties
the Company's 5% convertible secured debentures due March 15, 2003 (as such
debentures may be supplemented, amended, or otherwise modified from time to
time, the "1999 Debentures"; each such holder of 1999 Debentures, or any
permitted successor, assign or transferee thereof, a "1999 Holder") and warrants
to purchase Common Stock (the "1999 Warrants");

                  WHEREAS, in connection with the 1999 Purchase Agreement, the
Company granted to the 1999 Holders registration rights as set forth in Article
XI of the 1999 Purchase Agreement;

                  WHEREAS, in connection with the Bridge Loan Agreements, Galen
Partners III, L.P., Galen Partners International III, L.P. and Galen Employee
Fund III, L.P. (collectively, "Galen") holds warrants to purchase an aggregate
of 5,385,229 shares of the Company's common stock, $.01 par value per share (the
"Common Stock") as more particularly described on Schedule 2 hereof (the "Bridge
Loan Warrants");
<PAGE>
                  WHEREAS, the Company and Watson Pharmaceuticals, Inc.
("Watson") are parties to that certain Loan Agreement, dated as of March 29,
2000, as amended by a certain Amendment to Loan Agreement dated as of March 31,
2000 (as so amended, the "Loan Agreement");

                  WHEREAS, in consideration of further amending the Loan
Agreement to, among other things, extend the maturity date of the loan by
execution of a Second Amendment to the Loan Agreement dated as of December __,
2002, simultaneously with the execution of this Agreement, the Company will
issue to Watson a warrant (the "Watson Warrant") to purchase 10,700,665 shares
of the Common Stock;

                  WHEREAS, in connection with the 2002 Purchase Agreement, all
of the holders (except Galen) (the "Recap Shareholders") of the 1998 Warrants
and the 1999 Warrants have entered into an agreement (the "Recapitalization
Agreement"), dated the date hereof, to recapitalize their interests in the
Company by, inter alia, exchanging their respective warrants for shares of
Common Stock (the "Recap Shares");

                  WHEREAS, the Company and certain purchasers are parties to
that certain Debenture Purchase Agreement, dated the date hereof (as such
agreement may be supplemented, amended, or otherwise modified from time to time,
the "2002 Purchase Agreement"), whereby the Company issued to such parties the
Company's 5% convertible senior secured debentures due March 31, 2006 (as such
debentures may be supplemented, amended, or otherwise modified from time to
time, the "2002 Debentures"; each such holder of 2002 Debentures, or any
permitted successor, assign or transferee thereof, a "2002 Holder");

                  WHEREAS, in connection with the 2002 Purchase Agreement, the
Company has agreed to grant to the 2002 Holders registration rights as set forth
in this Agreement;

                  WHEREAS, the 1998 Holders desire to terminate the
registration rights provisions of the 1998 Purchase Agreement, the 1999 Holders
desire to terminate the registration rights provisions of the 1999 Purchase
Agreement, the holders of the 1998 Warrants desire to terminate the registration
rights applicable to the 1998 Warrants, the holders of the 1999 Warrants desire
to terminate the registration rights applicable to the 1999 Warrants, and Galen
desires to terminate the registration rights applicable to the Bridge Loan
Warrants and such parties desire to enter into this Agreement in lieu therefor
to provide for generally applicable registration rights for all such parties, to
the extent applicable, and to Watson and the 2002 Holders;

                  WHEREAS, the Company desires to grant and Watson, the 1998
Holders, the 1999 Holders, the 2002 Holders, the Recap Shareholders and Galen
desire to obtain, certain registration rights in connection with the Recap
Shares, the Watson Warrant, the 1998 Debentures, the 1999 Debentures, the 1998
Warrants held by Galen, the 1999 Warrants held by Galen, the Bridge Loan
Warrants and the 2002 Debentures (collectively, the "Securities"); and

                                        2
<PAGE>
                  WHEREAS, unless otherwise provided in this Agreement,
capitalized terms used herein shall have the meanings set forth in Section 14
hereof.

                  NOW, THEREFORE, in consideration of the foregoing and the
mutual covenants and promises contained herein, the parties agree as follows:

1.       Demand Registrations.

(A)      Requests for Registration. The Holders may request registration under
the Securities Act of all or any part of their Registrable Securities as
provided for below in Section 1(b). Within ten days after receipt of any such
request, the Company will give written notice of such requested registration to
all other Holders of Registrable Securities. The Company will include in such
registration all Registrable Securities with respect to which it has received
written requests for inclusion therein within 30 days after receipt of the
Company's notice. The Company shall cause its management to cooperate fully and
to use its best efforts to support the registration of the Registrable
Securities and the sale of the Registrable Securities pursuant to such
registration as promptly as is practicable. Such cooperation shall include, but
not be limited to, management's attendance and reasonable presentations in
respect of the Company at road shows with respect to the offering of Registrable
Securities. The registration requested under this Section 1 is referred to
herein as a "Demand Registration".

(B)      Number of Registrations. The Holders of Registrable Securities will be
entitled to request the following number and types of registrations: (i) Galen
shall be entitled to request two Demand Registrations on Form S-1 (or any
successor to such form), (ii) Watson shall be entitled to request two Demand
Registrations on Form S-1 (or any successor to such form), (iii) the Holders of
at least 20% of the Registrable Securities then outstanding shall be entitled to
request one Demand Registration on Form S-1 (or any successor to such form),
provided that all Demand Registrations requested pursuant to subsections (i) and
(ii) above shall be deemed to have occurred prior to the Demand Registration
pursuant to this subsection (iii), and (iv) the Holders of Registrable
Securities will be entitled to unlimited Demand Registrations on Form S-3 (or
any successor to such form), for which the Company will pay all Registration
Expenses. A registration will not count as a Demand Registration (x) until it
has become effective, (y) the Holders have sold, in the aggregate, no less than
50% of the shares of Registrable Securities requested to be registered in the
Demand Registration and (z) if the offering of the Registrable Securities
pursuant to such registration is interfered with for any reason by any stop
order, injunction or other order or requirement of the Commission (other than
any stop order, injunction or other requirement of the Commission prompted by
acts or omissions of Holders of Registrable Securities); provided, however, that
except as otherwise provided herein whether or not it becomes effective the
Company will pay all Registration Expenses in connection with any registration
so initiated.

(C)      Priority on Demand Registrations. If a Demand Registration is with
respect to an underwritten offering, and the managing underwriters advise the
Company in writing that in their opinion the number of Registrable Securities
requested to be included exceeds the number which can be sold in such offering,
the Company will include in such registration such number of

                                       3
<PAGE>
Shares, which in the opinion of such underwriters, may be sold, allocated among
the Holders electing to participate pro rata in accordance with the amounts of
securities requested to be so included by the respective Holders. If the amount
of such Registrable Securities does not exceed the maximum number which can be
sold in such offering, the Company may include such number of securities which
are not Registrable Securities in the Demand Registration which will not,
together with the Holder's Registrable Securities, exceed the maximum number
which can be sold in the Offering; provided, however, the Company will not
include in any Demand Registration any securities which are not Registrable
Securities without the written consent of the Holders of sixty and two-thirds
percent (66 2/3%) of the Registrable Securities participating in such
registration. A registration shall not count as a Demand Registration if less
than fifty percent (50%) of the Shares which any Holder desires to include
therein are not included due to the determination of the managing underwriters
referred to in the first sentence of this Section 1(c).

(D)      Restrictions on Demand Registrations. The Company will not be obligated
to effect any Demand Registration within six months after the effective date of
a previous registration in which the Holders of Registrable Securities were
given piggyback rights pursuant to Section 2 other than a registration of
Registrable Securities intended to be offered on a continuous or delayed basis
under Rule 415 or any successor rule under the Securities Act (a "Shelf
Registration").

2.       Piggyback Registrations.

(A)      Right to Piggyback. Whenever the Company proposes to register any of
its securities under the Securities Act (other than pursuant to a Demand
Registration or pursuant to a registration on Forms S-4 or S-8 or any successors
to such forms) and the registration form to be used may be used for the
registration and contemplated disposition of Registrable Securities (a
"Piggyback Registration"), the Company will give prompt written notice to all
the Holders of Registrable Securities. The Company will include in such
registration all Registrable Securities with respect to which the Company has
received written requests for inclusion therein within 30 days after the receipt
of the Company's notice, subject to any other priority cutback provisions below.

(B)      Piggyback Expenses. The Registration Expenses of the Holders of
Registrable Securities in such Piggyback Registration will be paid by the
Company.

(C)      Priority on Primary Registrations. If a Piggyback Registration is an
underwritten primary registration on behalf of the Company, and the managing
underwriters advise the Company in writing that in their opinion the number of
securities requested to be included in such registration exceeds the number
which can be sold in such offering, the Company will include in such
registration (i) first, the securities the Company proposes to sell, (ii)
second, the Registrable Securities, pro rata in accordance with the amounts of
Registrable Securities requested to be so included by each Requesting
Stockholder, and (iii) third, any other securities requested to be included in
such registration.

                                       4
<PAGE>
(D)      Priority on Secondary Registrations. If a Piggyback Registration is an
underwritten secondary registration on behalf of holders of the Company's
securities, and the managing underwriters advise the Company in writing that in
their opinion the number of securities requested to be included in such
registration exceeds the number which can be sold in such offering, the Company
will include in such registration (i) first, the securities requested to be
included therein by the holders requesting such registration, (ii) second, the
Registrable Securities, pro rata in accordance with the amounts of Registrable
Securities requested to be so included by each Requesting Stockholder, and (iii)
third, other securities requested to be included in such registration.

(E)      Other Restrictions. The Company hereby agrees that if it has previously
filed a registration statement with respect to Registrable Securities pursuant
to Section 1 or pursuant to this Section 2, and if such previous registration
has not been withdrawn or abandoned, the Company will not file or cause to be
effected any other registration of any of its equity securities or securities
convertible or exchangeable into or exercisable for its equity securities under
the Securities Act except on Form S-8 or any other similar form for employee
benefit plans, whether on its own behalf or at the request of any holder or
holders of such securities, until a period of at least six months has elapsed
from the effective date of such previous registration or, if sooner, until all
Registrable Securities included in such previous registration have been sold.

3.       Holdback Agreements.

(A)      Holders of Registrable Securities. The Investors and each other Holder
of Registrable Securities who is or becomes a party to this Agreement, agrees
not to effect any public sale or distribution of equity securities of the
Company, or any securities convertible into or exchangeable or exercisable for
such securities, during the seven days prior to and the 90-day period beginning
on the effective date of any underwritten Demand Registration or any
underwritten Piggyback Registration except as part of such underwritten
registration or, if sooner, until all Registrable Securities included within
such registration have been sold.

(B)      The Company. The Company agrees (i) not to effect any public sale or
distribution of its equity securities, or any securities convertible into or
exchangeable or exercisable for such securities, during the seven days prior to
and the 90-day period beginning on the effective date of any underwritten Demand
Registration or any underwritten Piggyback Registration except as part of such
underwritten registration or pursuant to registrations on Form S-8 or any other
similar form for employee benefit plans or, if sooner, until all Registrable
Securities included within such registration have been sold, and (ii) to use its
reasonable best efforts to cause each holder of its equity securities, or any
securities convertible into or exchangeable or exercisable for such securities,
purchased from the Company at any time after the date of this Agreement (other
than in a registered public offering) to agree not to effect any public sale or
distribution of any such securities during such period except as part of such
underwritten registration, if otherwise permitted or, if sooner, until all
Registrable Securities included within such registration have been sold;
provided, however, that the provisions of this Section 3(b) shall continue to
apply with respect to a registration until the provisions of Section 3(a) no
longer apply with respect to such registration.

                                       5
<PAGE>
(C)      Registration Procedures. Whenever the Holders of Registrable Securities
have requested that any Registrable Securities be registered pursuant to Section
1 or 2 of this Agreement, the Company shall use its best efforts to effect the
registration and the sale of such Registrable Securities in accordance with the
intended method of disposition thereof, and pursuant thereto the Company shall
as expeditiously as possible:

                  (i)      prepare and file with the Commission a registration
         statement with respect to such Registrable Securities, which
         registration statement will state that the Holders of Registrable
         Securities covered thereby may sell such Registrable Securities either
         under such registration statement or, at any Holder's proper request,
         pursuant to Rule 144 (or any successor rule under the Securities Act),
         and use its best efforts to cause such registration statement to become
         effective (provided that before filing a registration statement or
         prospectus or any amendments or supplements thereto, the Company will
         furnish to the counsel selected by (A) Galen, in the event of a Demand
         Registration requested pursuant to Section 1(b)(i), (B) Watson, in the
         event of a Demand Registration requested pursuant to Section 1(b)(ii),
         or (C) the Holders of sixty and two-thirds percent (66 2/3%) of the
         Registrable Securities included in such registration, in the event of
         any other registration, copies of all such documents proposed to be
         filed, which documents will be subject to the review of such counsel);

                  (ii)     prepare and file with the Commission such amendments
         and supplements to such registration statement and the prospectus used
         in connection therewith as may be necessary to keep such registration
         statement effective for the period set forth in Section 4(i) hereof and
         comply with the provisions of the Securities Act with respect to the
         disposition of all securities covered by such registration statement
         during such period in accordance with the intended methods of
         disposition by the sellers thereof set forth in such registration
         statement;

                  (iii)    furnish to each seller of Registrable Securities such
         number of copies of such registration statement, each amendment and
         supplement thereto, the prospectus included in such registration
         statement (including each preliminary prospectus) and such other
         documents as such seller may reasonably request in order to facilitate
         the disposition of the Registrable Securities owned by such seller;

                  (iv)     use its best efforts to register or qualify, if
         applicable, such Registrable Securities under such other securities or
         blue sky laws of such jurisdictions as any seller reasonably requests
         and do any and all other acts and things which may be reasonably
         necessary or advisable to enable such seller to consummate the
         disposition in such jurisdictions of the Registrable Securities owned
         by such seller (provided that the Company will not be required to (A)
         qualify generally to do business in any jurisdiction where it would not
         otherwise be required to qualify but for this subsection, (B) subject
         itself to taxation in any such jurisdiction, or (C) consent to general
         service of process in any such jurisdiction);

                                       6
<PAGE>
                  (v)      within one business day of its occurrence, notify
         each seller of such Registrable Securities, at any time when a
         prospectus relating thereto is required to be delivered under the
         Securities Act, of the happening of any event as a result of which the
         prospectus included in such registration statement contains an untrue
         statement of a material fact or omits to state any fact necessary to
         make the statements therein not misleading, and, at the request of any
         such seller, the Company will promptly prepare a supplement or
         amendment to such prospectus so that, as thereafter delivered to the
         purchasers of such Registrable Securities, such prospectus will not
         contain an untrue statement of a material fact or omit to state any
         fact necessary to make the statements therein not misleading;

                  (vi)     cause all such Registrable Securities to be listed on
         each securities exchange or market on which similar securities issued
         by the Company are then listed;

                  (vii)    provide a transfer agent and registrar for all such
         Registrable Securities not later than the effective date of such
         registration statement;

                  (viii)   make available for inspection by any seller of
         Registrable Securities, any underwriter participating in any
         disposition pursuant to such registration statement, and any attorney,
         accountant or other agent retained by any such seller or underwriter,
         all financial and other records, pertinent corporate documents and
         properties of the Company, and cause the Company's officers, directors
         and employees to supply all information reasonably requested by any
         such seller, underwriter, attorney, accountant or agent in connection
         with such registration statement;

                  (ix)     cause the Registrable Securities to be registered on
         such appropriate registration form or forms of the Commission as shall
         permit a delayed or continuous offering of the Registrable Securities
         pursuant to Rule 415 under the Securities Act and permit the
         disposition of the Registrable Securities in accordance with the method
         or methods of disposition requested by the Holders of sixty-six and
         two-thirds percent (66-2/3%) of the Registrable Securities included in
         such registration, and keep such registration statement effective until
         the Holders of a sixty-six and two-thirds percent (66-2/3%) of
         Registrable Securities included in such registration have completed the
         sale and distribution of the Registrable Securities;

                  (x)      if such registration is an underwritten registration,
         cause the Company's officers, directors and holders of in excess of one
         percent of the Company's outstanding Common to execute lock-up
         agreements, containing customary terms and provisions, required by an
         underwriter in any such registered offering restricting such parties
         from selling shares of the Company's Common Stock for a period of up to
         180 days; and

                  (xi)     furnish, at the request of any Holder requesting
         registration of Registrable Securities pursuant to Section 1 or 2, if
         the method of distribution is by means of an underwriting, on the date
         that the shares of Registrable Securities are delivered to the
         underwriters for sale pursuant to such registration, or if such
         Registrable Securities are not being sold through underwriters, on the
         date that the registration statement with

                                       7
<PAGE>
         respect to such shares of Registrable Securities becomes effective, (A)
         a signed opinion, dated such date, of the independent legal counsel
         representing the Company for the purpose of such registration,
         addressed to the underwriters, if any, and if such Registrable
         Securities are not being sold through underwriters, then to the Holders
         making such request, as to such matters as such underwriters or the
         Holders holding a majority of the Registrable Securities included in
         such registration, as the case may be, may reasonably request; and (B)
         letters dated such date and the date the offering is priced from the
         independent certified public accountants of the Company, addressed to
         the underwriters, if any, and if such Registrable Securities are not
         being sold through underwriters, then to the Holders making such
         request (x) stating that they are independent certified public
         accountants within the meaning of the Act and that, in the opinion of
         such accountants, the financial statements and other financial data of
         the Company included in the Registration Statement or the prospectus,
         or any amendment or supplement thereto, comply as to form in all
         material respects with the applicable accounting requirements of the
         Act and (y) covering such other financial matters (including
         information as to the period ending not more than five business days
         prior to the date of such letters) with respect to the registration in
         respect of which such letter is being given as such underwriters or the
         Holders holding a majority of the Registrable Securities included in
         such registration, as the case may be, may reasonably request and as
         would be customary in such a transaction.

4.       Registration Expenses. All Registration Expenses incurred in connection
with a registration, qualification or compliance pursuant to this Agreement
shall be borne by the Company, and all Selling Expenses shall be borne by the
Holders, the Requesting Stockholders and any other holders of the securities so
registered pro rata on the basis of the number of their shares so registered;
provided, however, that the Company shall not be required to pay any
Registration Expenses if, as a result of the withdrawal of a request for
registration by a majority of Registrable Securities (other than as a result of
any failure of the Company to comply with the terms of this Agreement, or the
disclosure of any adverse development relating to the Company after the initial
request for registration by any Holder), the registration statement does not
become effective, in which case the Holders and Requesting Stockholders
requesting registration shall bear such Registration Expenses pro rata on the
basis of the number of their shares so included in the registration request,
and, further, that such registration shall not be counted as a Demand
Registration pursuant to Section 1.

5.       Indemnification.

(A)      The Company will indemnify each Holder, each Holder's officers,
directors, employees, agents, members and partners, and each Person controlling,
controlled by or under common control with such Holder, with respect to which
registration, qualification or compliance of such Holder's securities has been
effected pursuant to this Agreement, and each underwriter, if any, and each
Person who controls any underwriter, against all claims, losses, damages and
liabilities (or actions in respect thereof), joint or several, arising out of or
based on any untrue statement (or alleged untrue statement) of a material fact
contained in any registration statement, prospectus, offering circular or other
document (including any related registration statement notification or the like)
incident to any such registration, qualification or compliance,

                                       8
<PAGE>
or based on any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, or any violation by the Company of the Securities Act or any rule or
regulation thereunder applicable to the Company and relating to action or
inaction required of the Company in connection with any such registration,
qualification or compliance, and will reimburse each such Holder, each Holder's
officers, directors, employees, agents, members and partners, and each Person
controlling each such Holder, each such underwriter and each Person who controls
any such underwriter, for any legal and any other expenses reasonably incurred
in connection with investigating or defending any such claim, loss, damage,
liability or action, provided that the Company will not be liable to a Holder in
any such case to the extent that any such claim, loss, damage, liability or
action arises out of or is based on any untrue statement or omission of material
fact based upon written information furnished to the Company by such Holder or
underwriter and stated to be specifically for use therein.

(B)      Each Holder and Requesting Stockholder will severally not jointly, if
Registrable Securities held by it are included in the securities as to which
such registration, qualification or compliance is being effected, indemnify the
Company, each of the Company's directors and officers and each underwriter, if
any, of the Company's securities covered by such registration statement, each
Person who controls the Company or such underwriter within the meaning of the
Securities Act and the rules and regulations thereunder, each other Holder,
Requesting Stockholder or any other holder of securities included in the
offering and each of their respective officers, directors, employees, agents,
members and partners, and each Person controlling such other Holder, Requesting
Stockholder and any other holders of securities included in the offering,
against all claims, losses, damages and liabilities (or actions in respect
thereof), joint or several, arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document incident to any such
registration, qualification or compliance, or based on any omission (or alleged
omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the
Company, its officers and directors, each underwriter, each Person controlling
the Company or such underwriter, each other Holder and Requesting Stockholders,
their officers, directors, employees, agents, members, partners and control
persons for any legal or any other expenses reasonably incurred in connection
with investigating or defending any such claim, loss, damage, liability or
action, in each case to the extent, but only to the extent, that such untrue
statement (or alleged untrue statement) or omission (or alleged omission) is
made in such registration statement, prospectus, offering circular or other
document in reliance upon and in conformity with written information furnished
to the Company by such Holder or Requesting Stockholder and stated to be
specifically for use therein; provided, however, that the obligations of each
such Holder and Requesting Stockholder hereunder shall be limited to an amount
equal to the net proceeds (after deduction of underwriting discounts and selling
commissions, if any) received by each such Holder or Requesting Stockholder of
securities sold as contemplated herein.

(C)      Each party entitled to indemnification under this Section 5 (the
"Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any

                                       9
<PAGE>
litigation resulting therefrom, provided that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the Indemnified Party (whose approval shall not
be unreasonably withheld) and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement unless such failure
has had a material adverse effect on such claim. The parties to this Agreement
reserve any rights to claim under this Agreement for damages actually incurred
by reason of any failure of the Indemnified Party to give prompt notice of a
claim. To the extent counsel for the Indemnifying Party shall in such counsel's
reasonable judgment, have a conflict in representing an Indemnified Party in
conjunction with the Indemnifying Party or other Indemnified Parties, such
Indemnified Party shall be entitled to separate counsel at the expense of the
Indemnifying Party subject to the approval of such counsel by the Indemnified
Party (whose approval shall not be unreasonably withheld). No Indemnifying
Party, in the defense of any such claim or litigation, shall, except with the
consent of each Indemnified Party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from
all liability in respect of such claim or litigation. Each Indemnified Party
shall furnish such information regarding itself or the claim in question as an
Indemnifying Party may reasonably request in writing and as shall be reasonably
required in connection with the defense of such claim and any litigation
resulting therefrom.

                  6.       Restrictive Legend. Each certificate representing (a)
the Securities or (b) any Shares or other securities issued in respect thereof,
upon any stock split, stock dividend, recapitalization, merger, consolidation or
similar event shall be stamped or otherwise imprinted with a legend in the
following form (in addition to any legend required under applicable state
securities laws and any other applicable agreement(s)):

                  "THIS WARRANT/DEBENTURE [AND THE COMMON STOCK ISSUABLE UPON
                  COVERSION HEREOF] HAVE NOT BEEN REGISTERED UNDER THE
                  SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), NOR ANY STATE
                  SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED,
                  HYPOTHECATED OR OTHERWISE TRANSFERRED UNTIL (1) A REGISTRATION
                  STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND
                  ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE COMPANY
                  RECEIVES AN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL
                  TO THE HOLDER OF SUCH [WARRANT/DEBENTURE AND/OR COMMON STOCK]
                  REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
                  [WARRANT/DEBENTURE AND/OR COMMON STOCK] MAY BE PLEDGED, SOLD,
                  ASSIGNED, HYPOTHECATED OR TRANSFERRED WITHOUT AN EFFECTIVE
                  REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE
                  SECURITIES LAWS."

                                       10
<PAGE>
                  7.       Information by the Holders and Requesting
Stockholders. Each Holder of Registrable Securities, and each Requesting
Stockholder holding securities included in any registration, shall furnish to
the Company such information regarding such Holder or Requesting Stockholder and
the distribution proposed by such Holder or Requesting Stockholder as the
Company may reasonably request in writing and as shall be reasonably required in
connection with any registration, qualification or compliance referred to in
this Agreement.

                  8.       Limitations on Registration of Issues of Securities.
From and after the date of this Agreement, the Company shall not enter into any
agreement with any holder or prospective holder of any securities of the Company
giving such holder or prospective holder the right to require the Company to
register any securities of the Company that are more favorable to such holder or
prospective holder than the rights granted under this Agreement.

                  9.       Rule 144 Reporting. With a view to making available
the benefits of certain rules and regulations of the Commission which may permit
the sale of the Restricted Securities to the public without registration, the
Company agrees to:

                           (a)      make and keep public information available
         as those terms are understood and defined and interpreted in and under
         Rule 144 under the Securities Act ("Rule 144"), at all times from and
         after the date hereof;

                           (b)      file with the Commission in a timely manner
         all reports and other documents required of the Company under the
         Securities Act and the Exchange Act at any time after it has become
         subject to such reporting requirements; and

                           (c)      so long as the Holders own any Restricted
         Securities, furnish to the Holders forthwith upon request a written
         statement by the Company as to its compliance with the reporting
         requirements of Rule 144 and of the Securities Act and the Exchange Act
         (at any time after it has become subject to such reporting
         requirements), a copy of the most recent annual or quarterly report of
         the Company, and such other reports and documents so filed as any
         Holder may reasonably request in availing itself of any rule or
         regulation of the Commission allowing any Holder to sell any such
         securities without registration.

                  10.      Participation in Underwritten Registrations. Subject
to the right of any Holder or Holders to withdraw any request for registration,
no Person may participate in any underwritten registration hereunder unless such
Person (a) agrees to sell such Person's securities on the basis provided in any
underwriting arrangements approved by the Persons entitled hereunder to approve
such arrangements and (b) completes and executes all reasonable and customary
questionnaires, powers of attorney, indemnities, underwriting agreements and
other documents required under the terms of such underwriting arrangements.

                  11.      Selection of Underwriters. If any Demand Registration
is an underwritten offering, (a) Galen, in the event of a Demand Registration
requested pursuant to Section 1(b)(i), (b) Watson, in the event of a Demand
Registration requested pursuant to Section 1(b)(ii), and (c) the Holders of
sixty and two-thirds percent (66 2/3%) of the Registrable Securities included in
such registration, in the event of any other registration shall have the right
to select the

                                       11
<PAGE>
investment banking firm to be lead manager of the offering, subject to the
approval of the Company (which approval will not be unreasonably withheld). If
any registration other than a Demand Registration is an underwritten offering,
the Company will have the right to select the investment banking firm to be lead
manager of the offering, subject to the approval of the Holders of sixty and
two-thirds percent (66 2/3%) of the Registrable Securities included in such
registration (which approval will not be unreasonably withheld).

                  12.      Termination of Registration Rights. The rights of
Holders to request a Demand Registration or participate in a Piggyback
Registration shall expire on March 31, 2008.

                  13.      Termination of Other Registration Rights Agreements.

                  (a)      The 1998 Holders hereby agree and acknowledge that in
consideration for the registration rights granted hereunder that Article XI (or
any successor or equivalent article or provision) of the 1998 Purchase Agreement
and any other agreement, instrument or understanding that grants or purports to
grant registration rights to such parties are hereby terminated and of no
further force or effect.

                  (b)      The holders of the 1998 Warrants hereby agree and
acknowledge that in consideration for the registration rights granted hereunder
that Article XI (or any successor or equivalent article or provision) of the
1998 Purchase Agreement and any other agreement, instrument or understanding
that grants or purports to grant registration rights to such parties are hereby
terminated and of no further force or effect.

                  (c)      The 1999 Holders hereby agree and acknowledge that in
consideration for the registration rights granted hereunder that Article XI (or
any successor or equivalent article or provision) of the 1999 Purchase Agreement
and any other agreement, instrument or understanding that grants or purports to
grant registration rights to such parties are hereby terminated and of no
further force or effect.

                  (d)      The holders of the 1999 Warrants hereby agree and
acknowledge that in consideration for the registration rights granted hereunder
that Article XI (or any successor or equivalent article or provision) of the
1999 Purchase Agreement and any other agreement, instrument or understanding
that grants or purports to grant registration rights to such parties are hereby
terminated and of no further force or effect.

                  (e)      Galen hereby agrees and acknowledges that in
consideration for the registration rights granted hereunder that any provision
or Section in the Bridge Loan Agreements, the Bridge Loan Warrants and any other
agreement, instrument or understanding that grants or purports to grant
registration rights to Galen are hereby terminated and of no further force or
effect.

                  14.      Definitions. As used herein, the following terms have
the following meanings:

                  "Act" means the Securities Act of 1933, as amended.

                                       12
<PAGE>
                  "Agreement" means this Registration Rights Agreement.

                  "Bridge Loan Agreements" means any and all of the separate
         Bridge Loan Agreements between the Company, Galen Partners III, L.P.
         and the other parties listed on the signature pages thereto entered
         into between such parties commencing as of August 12, 1998 through and
         including December __, 2002 pursuant to which the Bridge Loan Warrants
         were issued, including, without limitation, that certain Bridge Loan
         Agreement dated as of August 15, 2001 among the Company, Galen Partners
         III, L.P., Galen Partners International III L.P., Galen Employee Fund
         III, L.P., those individuals listed on the signature page thereto, and
         Galen Partners III, L.P., as agent for the lenders, as amended by the
         First Amendment to Bridge Loan Agreement dated as of January 8, 2002,
         the Second Amendment to Bridge Loan Agreement dated as of April 5,
         2002, and the Third Amendment to Bridge Loan Agreement dated as of May
         8, 2002, as such may be supplemented, amended or otherwise modified
         from time to time.

                  "Common Stock" has the meaning set forth in the recitals.

                  "Commission" means the Securities and Exchange Commission.

                  "Company" has the meaning set forth in the preamble.

                  "Demand Registration" has the meaning set forth in Section
         1(a) of this Agreement.

                  "Exchange Act" means the Securities Exchange Act of 1934, as
         amended.

                  "Holders" means the Investors or any Person to whom an
         Investor or transferee(s) of an Investor has assigned, transferred or
         otherwise conveyed the Securities or the Shares.

                  "Indemnified Party" has the meaning set forth in Section 5
         hereof.

                  "Indemnifying Party" has the meaning set forth in Section 5
         hereof.

                  "Investors" has the meaning set forth in the preamble.

                  "Loan Agreement" has the meaning set forth in the recitals.

                  "1998 Debentures" has the meaning set forth in the recitals.

                  "1998 Holder" has the meaning set forth in the recitals.

                  "1998 Purchase Agreement" has the meaning set forth in the
         recitals.

                  "1998 Warrants" has the meaning set forth in the recitals.

                                       13
<PAGE>
                  "1999 Debentures" has the meaning set forth in the recitals.

                  "1999 Holder" has the meaning set forth in the recitals.

                  "1999 Purchase Agreement" has the meaning set forth in the
         recitals.

                  "1999 Warrants" has the meaning set forth in the recitals.

                  "Person" means any individual, corporation, limited liability
         company, partnership, association, trust or any other entity or
         organization, including a government or political subdivision or an
         agency or instrumentality thereof.

                  "Piggyback Registration" has the meaning set forth in Section
         2 of this Agreement.

                  "Registrable Securities" means any Shares issued or issuable
         upon the exercise or conversion of the Securities (including any
         Securities that may be issued as interest with respect to any Security)
         or in respect of the Shares issued or issuable upon the exercise or
         conversion of any Securities upon any stock split, stock dividend,
         recapitalization or similar event.

                  "Registration Expenses" means all expenses incurred by the
         Company in compliance with Sections 1 and 2 hereof, including, without
         limitation, all registration and filing fees, printing expenses, fees,
         and disbursements of counsel for the Company and blue sky fees and
         expenses, reasonable fees and disbursements for one counsel, as such
         counsel is selected in accordance with Section 4(a), and the expense of
         any special audits incident to or required by any such registration,
         exclusive of the Selling Expenses.

                  "Restricted Securities" means the securities of the Company
         required to bear or bearing the legend set forth in Section 6 of this
         Agreement.

                  "Requesting Stockholders" means holders of securities of the
         Company entitled to have securities included in any registration
         pursuant to Section 2 and who shall request such inclusion.

                  "Rule 144" has the meaning set forth in Section 9 of this
         Agreement.

                  "Securities" has the meaning set forth in the recitals.

                  "Securities Act" means the Securities Act of 1933, as amended.

                  "Selling Expenses" means all underwriting discounts and
         selling commissions applicable to the sale of Registrable Securities
         and, except as otherwise provided in "Registration Expenses", all fees
         and disbursements of counsel for any Holder.

                                       14
<PAGE>
                  "Shares" means the shares of Common Stock which may be issued
         upon the exercise of all or a portion of the Securities. The term
         Shares does not include any other shares of Common Stock or other
         capital stock of the Company.

                  "Shelf Registration" has the meaning set forth in Section 1 of
         this Agreement.

                  "2002 Debentures" has the meaning set forth in the recitals.

                  "2002 Holder" has the meaning set forth in the recitals.

                  "2002 Purchase Agreement" has the meaning set forth in the
         recitals.

                  "Watson Warrant" has the meaning set forth in the recitals.

                  15.      Remedies. Any Person having rights under any
provision of this Agreement shall be entitled to enforce such rights
specifically to recover damages caused by reason of any breach of any provision
of this Agreement and to exercise all other rights granted by law. The parties
hereto agree and acknowledge that money damages may not be an adequate remedy
for any breach of the provisions of this Agreement and that any party may in its
sole discretion apply to any court of law or equity of competent jurisdiction
(without posting any bond or other security) for specific performance and for
other injunctive relief in order to enforce or prevent violation of the
provisions of this Agreement.

                  16.      Amendments and Waivers. The provisions of this
Agreement may be amended or waived only upon the prior written consent of the
Company and the Holders of sixty and two-thirds percent (66 2/3%) of the
Registrable Securities, provided that the prior written consent of all of the
Holders will be required to amend Section 1 and 2 hereof.

                  17       Delays or Omissions. No delay or omission to exercise
any right, power or remedy accruing to any Investor or Holder upon any breach or
default of the Company under this Agreement shall impair any such right, power
or remedy of such Holder or Investor nor shall it be construed to be a waiver of
any such breach or default, or an acquiescence, therein, or of or in any similar
breach or default thereafter occurring; nor shall any waiver of any single
breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any holder of any breach or default under this
Agreement, or any waiver on the part of any Investor or Holder of any provisions
or conditions of this Agreement must be, made in writing and shall be effective
only to the extent specifically set forth in such writing. All remedies, either
under this Agreement or by law or otherwise afforded to any holder, shall be
cumulative and not alternative.

                  18.      Successors and Assigns. All covenants and agreements
in this Agreement by or on behalf of any of the parties hereto shall bind and
inure to the benefit of the respective successors and assigns of the parties
hereto whether so expressed or not. In addition, whether or not any express
assignment has been made, the provisions of this Agreement which are for the
benefit of the Holders of Registrable Securities are also for the benefit of,
and enforceable by, any subsequent holder of Registrable Securities. The
registration rights provided in this

                                       15
<PAGE>
Agreement may be transferred without restriction and shall inure to and be
enforceable by any and all Holders of Registrable Securities, including, without
limitation, any successors, assigns, transferees, heirs, executors and
administrators of the Investors.

                  19.      Severability. Unless otherwise expressly provided
herein, each Investor's or Holders rights and obligations hereunder are several
rights and obligations, not rights and obligations jointly held with any other
person. In case any provision of this Agreement shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

                  20.      Counterparts; Facsimile Transmission. This Agreement
may be executed simultaneously in two or more counterparts, any one of which
need not contain the signatures of more than one party, but all such
counterparts taken together shall constitute one and the same Agreement. Each
party to this Agreement agrees that it will be bound by its own facsimilied
signature and that it accepts the facsimilied signature of each other party to
this Agreement.

                  21.      Descriptive Headings. The titles of the articles,
sections and subsections of this Agreement are for convenience of reference only
and are not to be considered in construing this Agreement.

                  22.      Governing Law. This Agreement and the rights of the
parties hereunder shall be governed in all respects by the laws of the State of
New York wherein the terms of this Agreement were negotiated, excluding to the
greatest extent permitted by law any rule of law that would cause the
application of the laws of any jurisdiction other than the State of New York.

                  23.      Notices. All notices, demands or other communications
to be given or delivered under or by reason of the provisions of this Agreement
shall be in writing and shall be deemed to have been given when delivered
personally to the recipient, sent to the recipient by reputable overnight
courier service (charges prepaid) or 48 hours after deposited in the United
States mail, certified or registered to the recipient by postage prepaid or by
facsimile. Such notices, demands and other communications shall be sent to the
Investors and to any Holder at the addresses indicated on the Schedule of
Investors attached hereto and to the Company at the address of its corporate
headquarters or to such other address or to the attention of such other Person
as the recipient party has specified by prior written notice to the sending
party.

                      [THIS SPACE INTENTIONALLY LEFT BLANK]

                                       16
<PAGE>
                  IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date first written above.
                                       COMPANY

                                       HALSEY DRUG CO., INC.

                                       By:  ____________________________
                                            Name:  _____________________
                                            Title: _____________________

                                       WATSON

                                       WATSON PHARMACEUTICALS, INC.

                                       By:  ____________________________
                                            Name:  _____________________
                                            Title: _____________________

                                       17
<PAGE>
                                  2002 HOLDERS

<TABLE>
<S>                                          <C>
GALEN PARTNERS III, L.P.                     GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Claudius, L.L.C., General Partner        By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.                    610 Fifth Avenue, 5th Floor
New York, New York 10019                     New York, New York 10020

__________________________________________   _______________________________________________
By: Srini Conjeevaram                        By: Srini Conjeevaram
Its: General Partner                         Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                ESSEX WOODLANDS VENTURES FUND V, L.P.
By: Wesson Enterprises, Inc.                 By: Essex Woodlands Health Ventures V, L.L.C.,
610 Fifth Avenue, 5th Floor                      Its General Partner
New York, New York 10020                     190 South LaSalle Street, Suite 2800
                                             Chicago, IL 60603

__________________________________________   _______________________________________________
By: Bruce F. Wesson                          By: Immanuel Thangaraj
Its: General Partner                         Its: Managing Director

CARE CAPITAL INVESTMENTS II, L.P.            BERNARD SELZ
By: Care Capital II, LLC, General Partner    c/o Furman Selz
47 Hulfish Street, Suite 310                 230 Park Avenue
Princeton, NJ 08542                          New York, New York 10069

__________________________________________   _______________________________________________
By: David R. Ramsay
Its: Authorized Signatory

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania 19035                 Gladwyne, Pennsylvania 19035

__________________________________________   _______________________________________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey 07059

__________________________________________   _______________________________________________
</TABLE>

                                       18
<PAGE>
<TABLE>
<S>                                          <C>
GREG WOOD                                    ROGER GRIGGS
c/o D.R. International                       c/o Tom Jennings
7474 No. Figueroa Street                     7300 Turfway Road
Los Angeles, California  90041               Suite 300
                                             Florence, KY 41042

__________________________________________   _______________________________________________

GEORGE E. BOUDREAU
222 Elbow Lane
Haverford, PA  19041

__________________________________________
</TABLE>

                                       19
<PAGE>
                                  1998 HOLDERS

<TABLE>
<S>                                          <C>
                                             GALEN PARTNERS III, L.P.
                                             By: Claudius, L.L.C., General Partner
                                             610 Fifth Avenue, 5th Fl.
                                             New York, New York 10019

                                             _______________________________________________
                                             By: Srini Conjeevaram
                                             Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                 By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                  610 Fifth Avenue, 5th Floor
New York, New York 10020                     New York, New York 10020

__________________________________________   _______________________________________________
                                             By: Srini Conjeevaram
By: Bruce F. Wesson                          Its: General Partner
Its: General Partner

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island 02840                  Gladwyne, PA 19035

__________________________________________   _______________________________________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania 19035                 Gladwyne, Pennsylvania 19035

__________________________________________   _______________________________________________

GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania 19312
Los Angeles, California 90041

__________________________________________   _______________________________________________
</TABLE>

                                       20
<PAGE>
<TABLE>
<S>                                          <C>
ROBERT W. BAIRD & CO., INC., TTEE            ROBERT W. BAIRD & CO., INC., TTEE
FBO Connie Reicher IRA                       FBO Michael K. Reicher IRA
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________
By: Robert W. Baird                          By: Robert W. Baird
Its: Trustee                                 Its: Trustee

CONNIE REICHER TRUST                         MICHAEL REICHER TRUST
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________
By: Connie Reicher                           By: Michael Reicher
Its: Trustee                                 Its: Trustee

PETER CLEMENS                                STEPHANIE HEITMEYER
c/o Halsey Drug Co., Inc.                    17759 Road, Route 66
695 North Perryville Rd.                     Ft. Jennings, Ohio 45844
Crimson Building #2
Rockford, Ill. 61107

__________________________________________   _______________________________________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey 07059                     Warren, New Jersey 07059

__________________________________________   _______________________________________________

BERNARD SELZ
c/o Furman Selz
230 Park Avenue
New York, New York 10069

__________________________________________
</TABLE>

                                       21
<PAGE>
<TABLE>
<S>                                          <C>
VARSHA H. SHAH AS CUSTODIAN                  VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                           FOR SUMEET H. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey 07059                     Warren, New Jersey 07059

__________________________________________   _______________________________________________
By: Varshah H. Shah                          By: Varshah H. Shah
Its: Custodian                               Its: Custodian

MICHAEL RAINISCH                             ILENE RAINISCH
c/o Alvin Rainisch                           c/o Alvin Rainisch
315 Devon Place                              315 Devon Place
Morganville, New Jersey 07751                Morganville, New Jersey 07751

__________________________________________   _______________________________________________

KENNETH GIMBEL, IRA ACCOUNT                  KENNETH GIMBEL
FBO KENNETH GIMBEL                           2455 Montgomery Avenue
2455 Montgomery Avenue                       Highland Park, Ill. 60035
Highland Park, Ill. 60035

__________________________________________   _______________________________________________
By: ______________________________________
Its: Trustee

JESSICA K. CLEMENS                           JAKE P. CLEMENS
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________

BROOKE EMILY REICHER                         ALEC JOHN REICHER
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________
</TABLE>

                                       22
<PAGE>
<TABLE>
<S>                                          <C>
COURTNEY PAIGE REICHER                       DEANA REICHER
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________

MICHAEL K. REICHER II                        TODD ALLEN REICHER
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

__________________________________________   _______________________________________________
</TABLE>

                                       23
<PAGE>
                                  1999 HOLDERS

<TABLE>
<S>                                          <C>
ORACLE STRATEGIC PARTNERS, L.P.              GALEN PARTNERS III, L.P.
By: Oracle Strategic Capital L.L.C.,         By: Claudius, L.L.C., General Partner
General Partner                              610 Fifth Avenue, 5th Fl.
200 Greenwich Avenue                         New York, New York 10019
3rd Floor
Greenwich, CT 06830

__________________________________________   _______________________________________________
By: Joel Liffmann                            By: Srini Conjeevaram
Its: Authorized Agent                        Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                 By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                  610 Fifth Avenue, 5th Floor
New York, New York 10020                     New York, New York 10020

__________________________________________   _______________________________________________
By: Bruce F. Wesson                          By: Srini Conjeevaram
Its: General Partner                         Its: General Partner

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island 02840                  Gladwyne, PA 19035

__________________________________________   _______________________________________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania 19035                 Gladwyne, Pennsylvania 19035

__________________________________________   _______________________________________________
</TABLE>

                                       24
<PAGE>
<TABLE>
<S>                                          <C>
GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania  19312
Los Angeles, California  90041

_______________________________________      _________________________________

BERNARD SELZ
c/o Furman Selz
230 Park Avenue
New York, New York  10069

_______________________________________
</TABLE>

                                       25
<PAGE>
                            HOLDERS OF RECAP SHARES

<TABLE>
<S>                                          <C>
ORACLE STRATEGIC PARTNERS, L.P.              DANIEL HILL
By: Oracle Strategic Capital L.L.C.,         6725 Lynch Avenue
General Partner                              Riverbank, CA 95367
200 Greenwich Avenue
3rd Floor
Greenwich, CT 06830

_______________________________________      _________________________________
By:  Joel Liffmann
Its: Authorized Agent

BERNARD SELZ                                 PETER CLEMENS
c/o Furman Selz                              c/o Halsey Drug Co., Inc.
230 Park Avenue                              695 North Perryville Rd.
New York, New York  10069                    Crimson Building #2
                                             Rockford, Ill. 61107

_______________________________________      _________________________________

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island  02840                 Gladwyne, PA 19035

_______________________________________      _________________________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania  19035                Gladwyne, Pennsylvania  19035

_______________________________________      _________________________________

GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania  19312
Los Angeles, California  90041

_______________________________________      _________________________________
</TABLE>

                                       26
<PAGE>
<TABLE>
<S>                                          <C>
ROBERT W. BAIRD & CO., INC., TTEE            ROBERT W. BAIRD & CO., INC., TTEE
FBO Connie Reicher IRA                       FBO Michael K. Reicher IRA
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

_______________________________________      _________________________________
By:  Robert W. Baird                         By:  Robert W. Baird
Its: Trustee                                 Its: Trustee

CONNIE REICHER TRUST                         MICHAEL REICHER TRUST
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

_______________________________________      _________________________________
By:  Connie Reicher                          By:  Michael Reicher
Its: Trustee                                 Its: Trustee

KENNETH GIMBEL                               STEPHANIE HEITMEYER
2455 Montgomery Avenue                       17759 Road, Route 66
Highland Park, Ill. 60035                    Ft. Jennings, Ohio 45844

_______________________________________      _________________________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

_______________________________________      _________________________________

VARSHA H. SHAH AS CUSTODIAN                  VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                           FOR SUMEET H. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

_______________________________________      _________________________________
By:  Varshah H. Shah                         By:  Varshah H. Shah
Its: Custodian                               Its: Custodian
</TABLE>

                                       27
<PAGE>
<TABLE>
<S>                                          <C>
MICHAEL RAINISCH                             ILENE RAINISCH
c/o Alvin Rainisch                           c/o Alvin Rainisch
31 Congressional Road                        35 Congressional Road
Jackson, New Jersey 08527                    Jackson, New Jersey 08527

_______________________________________      _________________________________
</TABLE>

                                       28
<PAGE>
                                     GALEN

<TABLE>
<S>                                          <C>
GALEN PARTNERS III, L.P.
By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.
New York, New York  10019

______________________________________
By:  Srini Conjeevaram
Its: General Partner

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III,
By: Wesson Enterprises, Inc.                 L.P.
610 Fifth Avenue, 5th Floor                  By: Claudius, L.L.C., General Partner
New York, New York 10020                     610 Fifth Avenue, 5th Floor
                                             New York, New York  10020

______________________________________       _____________________________________
By:  Bruce F. Wesson                         By:  Srini Conjeevaram
Its: General Partner                         Its: General Partner
</TABLE>

                                       29
<PAGE>
                                   SCHEDULE 1

                             SCHEDULE OF INVESTORS

Watson:

Watson Pharmaceuticals, Inc.
311 Bonnie Circle
Corona, California 92880
Attention: Michael Boxer

Tel: ____________________
Fax: ____________________

                                  2002 HOLDERS

<TABLE>
<S>                                          <C>
GALEN PARTNERS III, L.P.                     GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Claudius, L.L.C., General Partner        By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.                    610 Fifth Avenue, 5th Floor
New York, New York  10019                    New York, New York  10020

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

GALEN EMPLOYEE FUND III, L.P.                ESSEX WOODLANDS VENTURES FUND V, L.P.
By: Wesson Enterprises, Inc.                 By: Essex Woodlands Health Ventures V,
610 Fifth Avenue, 5th Floor                  L.L.C., Its General Partner
New York, New York 10020                     190 South LaSalle Street, Suite 2800
                                             Chicago, IL 60603

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

CARE CAPITAL INVESTMENTS II, LP              BERNARD SELZ
                                             c/o Furman Selz
By: Care Capital II, LLC, as general         230 Park Avenue
    partner                                  New York, New York  10069

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       30
<PAGE>
<TABLE>
<S>                                          <C>
MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania  19035                Gladwyne, Pennsylvania  19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

GREG WOOD                                    GEORGE E. BOUDREAU
c/o D.R. International                       222 Elbow Lane
7474 No. Figueroa Street                     Havenford, PA  19041
Los Angeles, California  90041

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

ROGER GRIGGS
c/o Tom Griggs
7300 Turfway Road
Suite 300
Florence, KY  41042

Tel: ____________________
Fax: ____________________
</TABLE>

                                       31
<PAGE>
                                  1998 HOLDERS

<TABLE>
<S>                                          <C>
                                             GALEN PARTNERS III, L.P.
                                             By: Claudius, L.L.C., General Partner
                                             610 Fifth Avenue, 5th Fl.
                                             New York, New York  10019

                                             Tel: ____________________
                                             Fax: ____________________

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                 By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                  610 Fifth Avenue, 5th Floor
New York, New York 10020                     New York, New York  10020

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island  02840                 Gladwyne, PA 19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania  19035                Gladwyne, Pennsylvania  19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania  19312
Los Angeles, California  90041

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       32
<PAGE>
<TABLE>
<S>                                          <C>
BERNARD SELZ                                 ROBERT W. BAIRD & CO., INC., TTEE
c/o Furman Selz                              FBO Michael K. Reicher IRA
230 Park Avenue                              c/o Halsey Drug Co., Inc.
New York, New York  10069                    695 North Perryville Rd.
                                             Crimson Building #2
                                             Rockford, Ill. 61107

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

MICHAEL REICHER                              PETER CLEMENS
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill.  61107                        Rockford, Ill. 61107

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

CONNIE REICHER TRUST                         STEPHANIE HEITMEYER
c/o Halsey Drug Co., Inc.                    17759 Road, Route 66
695 North Perryville Rd.                     Ft. Jennings, Ohio 45844
Crimson Building #2
Rockford, Ill. 61107
                                             Tel: ____________________
Tel: ____________________                    Fax: ____________________
Fax: ____________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

VARSHA H. SHAH AS CUSTODIAN                  VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                           FOR SUMEET H. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       33
<PAGE>
                                  1999 HOLDERS

<TABLE>
<S>                                          <C>
ORACLE STRATEGIC PARTNERS, L.P.              GALEN PARTNERS III, L.P.
By: Oracle Strategic Capital L.L.C.,         By: Claudius, L.L.C., General Partner
General Partner                              610 Fifth Avenue, 5th Fl.
200 Greenwich Avenue                         New York, New York  10019
3rd Floor
Greenwich, CT 06830

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                 By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                  610 Fifth Avenue, 5th Floor
New York, New York 10020                     New York, New York  10020

                                             Tel: ____________________
Tel: ____________________                    Fax: ____________________
Fax: ____________________

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island  02840                 Gladwyne, PA 19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania  19035                Gladwyne, Pennsylvania  19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       34
<PAGE>
<TABLE>
<S>                                          <C>
GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania  19312
Los Angeles, California  90041

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

BERNARD SELZ
c/o Furman Selz
230 Park Avenue
New York, New York  10069

Tel: ____________________
Fax: ____________________
</TABLE>

                                       35
<PAGE>
                            HOLDERS OF RECAP SHARES

<TABLE>
<S>                                          <C>
ORACLE STRATEGIC PARTNERS, L.P.              DANIEL HILL
By: Oracle Strategic Capital L.L.C.,         6725 Lynch Avenue
General Partner                              Riverbank, CA 95367
200 Greenwich Avenue
3rd Floor
Greenwich, CT  06830

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

BERNARD SELZ                                 PETER CLEMENS
c/o Furman Selz                              c/o Halsey Drug Co., Inc.
230 Park Avenue                              695 North Perryville Rd.
New York, New York  10069                    Crimson Building #2
                                             Rockford, Ill. 61107

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

ALAN SMITH                                   PATRICK COYNE
21 Bedlow Avenue                             800 Merion Square Road
Newport, Rhode Island  02840                 Gladwyne, PA 19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

MICHAEL WEISBROT                             SUSAN WEISBROT
1136 Rock Creek Road                         1136 Rock Creek Road
Gladwyne, Pennsylvania  19035                Gladwyne, Pennsylvania  19035

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

GREG WOOD                                    DENNIS ADAMS
c/o D.R. International                       120 Kynlyn Road
7474 No. Figueroa Street                     Radnor, Pennsylvania  19312
Los Angeles, California  90041

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       36
<PAGE>
<TABLE>
<S>                                          <C>
ROBERT W. BAIRD & CO., INC., TTEE            ROBERT W. BAIRD & CO., INC., TTEE
FBO Connie Reicher IRA                       FBO Michael K. Reicher IRA
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

CONNIE REICHER TRUST                         MICHAEL REICHER TRUST
c/o Halsey Drug Co., Inc.                    c/o Halsey Drug Co., Inc.
695 North Perryville Rd.                     695 North Perryville Rd.
Crimson Building #2                          Crimson Building #2
Rockford, Ill. 61107                         Rockford, Ill. 61107

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

KENNETH GIMBEL                               STEPHANIE HEITMEYER
2455 Montgomery Avenue                       17759 Road, Route 66
Highland Park, Ill. 60035                    Ft. Jennings, Ohio 45844

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

VARSHA H. SHAH                               HEMANT K. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________

VARSHA H. SHAH AS CUSTODIAN                  VARSHA H. SHAH AS CUSTODIAN
FOR SACHIN H. SHAH                           FOR SUMEET H. SHAH
29 Christy Drive                             29 Christy Drive
Warren, New Jersey  07059                    Warren, New Jersey  07059

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       37
<PAGE>
<TABLE>
<S>                                          <C>
MICHAEL RAINISCH                             ILENE RAINISCH
c/o Alvin Rainisch                           c/o Alvin Rainisch
31 Congressional Road                        35 Congressional Road
Jackson, New Jersey 08527                    Jackson, New Jersey 08527

Tel: ____________________                    Tel: ____________________
Fax: ____________________                    Fax: ____________________
</TABLE>

                                       38
<PAGE>
                                     GALEN

<TABLE>
<S>                                          <C>
GALEN PARTNERS III, L.P.
By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Fl.
New York, New York  10019

Tel: ____________________
Fax: ____________________

GALEN EMPLOYEE FUND III, L.P.                GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Wesson Enterprises, Inc.                 By: Claudius, L.L.C., General Partner
610 Fifth Avenue, 5th Floor                  610 Fifth Avenue, 5th Floor
New York, New York 10020                     New York, New York  10020

                                             Tel: ____________________
Tel: ____________________                    Fax: ____________________
Fax: ____________________
</TABLE>

                                       39
<PAGE>
                                   SCHEDULE 2

                              BRIDGE LOAN WARRANTS

                                 See attached.

                                       40
<PAGE>
<TABLE>
<CAPTION>
                                                                                   GALEN PARTNERS           GALEN
                                     WARRANT EXERCISE      GALEN PARTNERS III,    INTERNATIONAL III,       EMPLOYEES
DATE OF WARRANT                           PRICE                  L.P.                   L.P.             FUND III, L.P.
<S>                                  <C>                   <C>                    <C>                    <C>
August 12, 1998                         $  2.2100               47,646                 4,611                  209
September 17, 1998                      $  1.8900               23,824                 2,305                  104
October 2, 1998                         $  1.7300               23,824                 2,305                  104
October 19, 1998                        $  1.5000                7,147                   692                   31
October 19, 1998                        $  1.4700               35,735                 3,459                  156
November 6, 1998                        $  1.4700               71,471                 6,917                  311
December 2, 1998                        $  1.3000              654,098                59,208                2,679
March 8, 1999                           $  1.1400               64,120                 5,804                  262
May 3, 1999                             $  1.1200               11,863                 1,073                   49
January 7, 2000                         $  1.4000               23,965                 2,169                   99
January 21, 2000                        $  1.4300               47,931                 4,339                  196
February 19, 2000                       $  1.1300               23,965                 2,169                   99
March 4, 2000                           $  1.5500               23,965                 2,169                   99
August 15, 2001                         $  3.0120              140,459                12,715                  576
January 9, 2002                         $  1.8370              146,157                13,230                  598
January 9, 2002                         $  1.8370               66,805                 6,047                  273
February 1, 2002                        $  1.8700               68,518                 6,202                  280
March 1, 2002                           $  2.0870               68,518                 6,202                  280
April 1, 2002                           $  2.0100               45,678                 4,135                  187
May 8, 2002                             $  2.1600            1,635,580               148,044                6,696
May 8, 2002                             $  2.1600              548,142                49,614                2,244
May 8, 2002                             $  2.1600              241,586                21,867                  989
June 3, 2002                            $  1.9000              215,194                19,478                  881
July 23, 2002                           $  1.7200              186,772                16,905                  765
July 23, 2002                           $  1.4500               82,220                 7,442                  337
August 5, 2002                          $  1.4200              151,245                13,690                  619
September 3, 2002                       $  1.5100              121,808                11,025                  499
October 1, 2002                         $  1.7545               93,386                 8,453                  382
November 4, 2002                        $  1.7565               11,775                 1,066                   48
November 12, 2002                       $  1.7730               10,151                   919                   42
November 21, 2002                       $  1.5770               24,971                 2,260                  102
                                                    -------------------------------------------------------------
                                                             4,918,519               446,514               20,196
                                                    =============================================================
</TABLE>

                                       41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]